SpringWorks Therapeutics Receivables

SpringWorks Therapeutics (SWTX) currently reports a receivables of $40M as of March 2025. That compares with $16M in the prior-year period — up 159.8% year over year. Use the charts on this page to explore SpringWorks Therapeutics's receivables history and peer comparisons.

SpringWorks Therapeutics's receivables increased from $16M to $40M — a 159.8% year-over-year increase (period ending March 2025). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

SpringWorks Therapeutics reported $40M in receivables as of March 2025. That compares with $16M in the prior-year period — up 159.8% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current receivables of $40M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for SpringWorks Therapeutics, and consider following SWTX for alerts when major investors trade the stock.

SpringWorks Therapeutics is classified in the Healthcare sector. On receivables, it currently shows $40M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing SWTX with unrelated industries.